Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.480
+0.010 (0.40%)
Jun 15, 2026, 4:00 PM EDT - Market closed
Anixa Biosciences Employees
Anixa Biosciences had 4 employees as of October 31, 2025. The number of employees decreased by 1 or -20.00% compared to the previous year.
Employees
4
Change (1Y)
-1
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$2,508,500
Market Cap
84.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 4 | -1 | -20.00% | 4 | 0 |
| Oct 31, 2024 | 5 | 0 | - | 5 | 0 |
| Oct 31, 2023 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2022 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2021 | 5 | 1 | 25.00% | 4 | 1 |
| Oct 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Adicet Bio | 102 |
| ImmuCell | 73 |
| Biomea Fusion | 41 |
| Aardvark Therapeutics | 40 |
| Cue Biopharma | 29 |
| NeurAxis | 24 |
| Rallybio | 14 |
ANIX News
- 4 days ago - Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium - PRNewsWire
- 6 days ago - Anixa Biosciences Quarterly report: Q2 2026 - Filings
- 12 days ago - Anixa Biosciences Slides: Corporate presentation - Filings
- 14 days ago - Anixa Biosciences: CIPO issues Notice of Allowance for patent - TheFly
- 14 days ago - Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance - PRNewsWire
- 5 weeks ago - Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer - TheFly
- 5 weeks ago - Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy - PRNewsWire
- 6 weeks ago - Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - PRNewsWire